However, the absence of a correlation of HRD status with PD‐L1 expression in these SCLC patients makes it possible to use these two factors together as indicators to predict the response to ICI therapy, similar to HRD status and TMB. This evidence concerns the gene CD274 and small cell lung carcinoma.